🟢 Structure Therapeutics is trading 4.1% up today on strong Phase 2b data for oral GLP-1 candidate

Structure Therapeutics is trading 4.1% up now at $48.91 as investors continue to react to strong Phase 2b data for its oral GLP-1 obesity candidate, aleniglipron.

• Recent publications and presentations highlighted double-digit, durable weight loss of up to 16% over 36–44 weeks.
• The data positions aleniglipron as a competitive oral obesity therapy, sustaining bullish sentiment for the company.
• The stock's performance is further supported by a broadly positive trend across the biotech sector.